通心络和氯吡格雷对急性冠脉综合征阿司匹林抵抗患者TXB2的干预研究

目的探讨通心络和氯吡格雷对急性冠脉综合征（ACS）阿司匹林抵抗（AR）患者血小板聚集率、血栓素B2（TXB2）的影响。方法选择70例急性冠脉综合征（ACS）阿司匹林抵抗（AR）患者,随机分为3组,A组常规治疗组,B组通心络组,C组氯吡格雷组;分别在治疗前和治疗后1月测定血小板聚集率、TXB2;比较3组治疗前后及治疗后不同组别上述指标的差异。结果（1）通心络和氯吡格雷均可使急性冠脉综合征阿司匹林抵抗患者血小板聚集率下降,氯吡格雷对ADP诱导的血小板聚集率的下降更明显;（2）通心络和氯吡格雷治疗后均可使急性冠脉综合征患者TXB2下降,与治疗前比较有显著性差异;同时与常规组治疗后比较也有显著性差异。而尽管氯吡格雷组使TXB2下降更明显,但与通心络组比较无统计学差异。结论通心络和氯吡格雷对急性冠状动脉综合征阿司匹林抵抗患者有抗血小板聚集作用,一定程度上可改善ACS患者的AR。

Effects of Tongxinluo and Clopidogrel on the treatment of patients with acute coronary syndrome

Objective To investigate the effects of Tongxinluo and clopidogrel on the treatment of patients with acute coronary syndrome（ACS） who had aspirin resistance（AR）. Methods A total of 70 patients with ACS who had AR were recruited. They were randomly assigned into group A who were treated with aspirin,group B who were treated with aspirin combination with Tongxinluo capsule, group C who were treated with aspirin combination with clopidogrel. The platelet aggregation function and TXB2 level were measureed before and after 1 month treat-ment. Results 1. The platelet aggregation function were significantly lower than before treatment both in group B and in group C, and the changes in group C was more manifest than that in group B2. The TXB2 level were significantly lower than before treatment both in group B and in group C. Post-treatment the TXB2 level in group B and group C were lower than that in group A. The level of TXB2 in group C was lower than that in group B,but it couldnot make statistics significance. Conclusion Our results indicate that Tongxinluo and clopidogrel both have beneficial ef-fects on inhibiting platelet activation in ACS patients with AR.